BMS-986406 / BMS, Ono Pharma - LARVOL DELTA

A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors (clinicaltrials.gov) - P1 | N=77 | Completed | Sponsor: Bristol-Myers Squibb | Active, not recruiting ➔ Completed | N=154 ➔ 77

Combination therapy • Enrollment change • Metastases • Monotherapy • Trial completion • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Ductal Adenocarcinoma • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

Developing personalized immunotherapy strategies using an ex vivo tumor fragment platform (EACR 2024) - "We cultured PDTFs from four cancer types (kidney, lung, skin, ovary) that were either left untreated or exposed to different agents including anti-PD-1 (nivolumab), anti-LAG3 (relatlimab), anti-ILT4 (BMS-986406), anti-CCR8 (BMS-986340) and/or JNK inhibitor (BMS-986360). Whereas in some tumors single or dual checkpoint blockade could enhance immune activity, most tumors required targeting of additional pathways to overcome immune resistance. Notably, individual tumors showed response to distinct treatment combinations, highlighting the need for developing personalized immunotherapy strategies.Conclusion Translational studies using patient-derived tumor models may help to identify rational immunotherapy combinations overcoming anti-PD-1 resistance and their biomarkers, and to prioritize them for clinical development."

IO biomarker • Preclinical • Oncology • CCR8

Developing personalized immunotherapy strategies using an ex vivo tumor fragment platform (EACR 2024) - "We cultured PDTFs from four cancer types (kidney, lung, skin, ovary) that were either left untreated or exposed to different agents including anti-PD-1 (nivolumab), anti-LAG3 (relatlimab), anti-ILT4 (BMS-986406), anti-CCR8 (BMS-986340) and/or JNK inhibitor (BMS-986360). Whereas in some tumors single or dual checkpoint blockade could enhance immune activity, most tumors required targeting of additional pathways to overcome immune resistance. Notably, individual tumors showed response to distinct treatment combinations, highlighting the need for developing personalized immunotherapy strategies.Conclusion Translational studies using patient-derived tumor models may help to identify rational immunotherapy combinations overcoming anti-PD-1 resistance and their biomarkers, and to prioritize them for clinical development."

IO biomarker • Preclinical • Oncology • CCR8

A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors (clinicaltrials.gov) - P1 | N=154 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Trial completion date: Jul 2026 ➔ Jul 2024 | Trial primary completion date: Apr 2026 ➔ Jul 2024

Combination therapy • Metastases • Monotherapy • Trial completion date • Trial primary completion date • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Ductal Adenocarcinoma • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors (clinicaltrials.gov) - P1 | N=154 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Recruiting ➔ Active, not recruiting

Combination therapy • Enrollment closed • Metastases • Monotherapy • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Ductal Adenocarcinoma • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors (clinicaltrials.gov) - P1 | N=154 | Recruiting | Sponsor: Bristol-Myers Squibb | N=112 ➔ 154

Combination therapy • Enrollment change • Metastases • Monotherapy • Breast Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Ductal Adenocarcinoma • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors (clinicaltrials.gov) - P1 | N=112 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting | Trial completion date: Sep 2025 ➔ Jul 2026 | Trial primary completion date: Mar 2024 ➔ Apr 2026

Combination therapy • Enrollment open • Monotherapy • Trial completion date • Trial primary completion date • Breast Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer